Back to top

Vertex Pharmaceuticals price target raised to $672 from $605 at BofA

BofA raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $672 from $605 and keeps a Buy rating on the shares after competitor Sionna...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Vertex Pharmaceuticals Incorporated (VRTX)